Physiomics PLC Trading update (9990U)
04 Agosto 2020 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 9990U
Physiomics PLC
04 August 2020
4 August 2020
Physiomics plc
("Physiomics" or "the Company")
Trading update
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to confirm that, based on its
unaudited management accounts for the year ended 30 June 2020, the
Company is trading in line with analyst expectations.
Trading for the current financial year has started well with a
further contract with Bicycle Therapeutics (announced on 30 June
2020), a strong continuing relationship with Merck KGaA as well as
a maiden contract (announced 31 July 2020) with Astellas, a
Japanese global pharmaceutical company, for a modelling project
involving Physiomics' Virtual Tumour(TM) immuno-oncology model. In
addition, the Company's investment in additional marketing
capability has led to an increased volume of introductory calls
with potential new clients, some of which the Board hopes will be
converted into further projects in the second half of this calendar
year.
Net cash as at 30 June 2020, stood at GBP1.1m, based on the
Company's unaudited management accounts, strengthened by an
oversubscribed placing announced on 27 May 2020, which raised gross
proceeds of GBP0.83m.
The Company expects to publish its final audited results for the
year ending 30 June 2020 during the week commencing 28 September
2020.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
For more information please visit:
www.physiomics.co.uk
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTUPUPPRUPUGRW
(END) Dow Jones Newswires
August 04, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024